In the KEYNOTE-407, KEYNOTE-189, and IMPOWER-130 studies (1–3), platinum-based double-chemotherapy plus anti-PD-1/PD-L1 (such as atezolizumab and pembrolizumab) showed significantly higher objective response, longer progression-free survival (PFS), and overall survival (OS) than chemotherapy alone in patients with metastatic NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.